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Abstract Heterotrimeric cardiac troponin (cTn) is a
critical component of the thin filament regulatory complex
in cardiac muscle. Two of the three subunits, cTnI and
cTnT, are subject to post-translational modifications such
as proteolysis and phosphorylation, but linking modifica-
tion patterns to function remains a major challenge. To
obtain a global view of the biochemical state of cTn in
native tissue, we performed high resolution top–down mass
spectrometry of cTn heterotrimers from healthy adult rat
hearts. cTn heterotrimers were affinity purified, desalted
and then directly subjected to mass spectrometry using a 7
Tesla Thermo LTQ-FT-ICR instrument equipped with an
ESI source. Molecular ions for N-terminally processed and
acetylated cTnI and cTnT were readily detected as were
other post-translationally modified forms of these proteins.
cTnI was phosphorylated with a distribution of un-, mono-
and bisphosphorylated forms of 41 ± 3%, 46 ± 1%,
13 ± 3%, respectively. cTnT was predominantly mono-
phosphorylated and partially proteolyzed at the Glu29-Pro30
peptide bond. Also observed in high resolution spectra
were ‘shadow’ peaks of similar intensity to ‘parent’ peaks
exhibiting masses of cTnI?16 Da and cTnT?128 Da,
subsequently shown by tandem mass spectrometry (MS/
MS) to be single amino acid polymorphisms. Intact and
protease-digested cTn subunits were fragmented by elec-
tron capture dissociation or collision activated dissociation
to localize an Ala/Ser polymorphism at residue 7 of cTnI.
Similar analysis of cTnT localized an additional Gln within
a three residue alternative splice site beginning at residue
192. Besides being able to provide unique insights into the
global state of post-translational modification of cTn sub-
units, high resolution top–down mass spectrometry readily
revealed naturally occurring single amino acid sequence
variants including a genetic polymorphism at residue 7 in
cTnI, and an alternative splice isoform that affects a
putative hinge region around residue 192 of cTnT, all of
which co-exist within a single rat heart.
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Introduction
The heterotrimeric protein troponin (cTn) together with
tropomyosin (Tm) make up the thin filament associated
Ca2? regulatory switch in cardiac muscle (Solaro 2008).
Two subunits of the cTn complex, cTnI and cTnT, are
widely used in clinical medicine as biomarkers of cardiac
injury (Jaffe et al. 2006). Moreover, cTn subunits have
received considerable attention as sarcomeric protein genes
harboring mutations that cause familial hypertrophic car-
diomyopathy (HCM) in humans (Harada and Morimoto
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2004). cTnI and cTnT are known to be key substrates for
regulatory kinases including protein kinase A, protein
kinase C and many others (Pi et al. 2002, 2003; Sumandea
et al. 2003; Vahebi et al. 2005; Solaro 2008). Proteolytic
cleavage of troponin subunits has also been suggested to
contribute to cardiac syndromes such as myocardial stun-
ning and chronic heart failure (Murphy 2006).
Traditional strategies for establishing the state of post-
translational modification of cTn rely on 32P-incorporation,
tryptic peptide mapping (Jideama et al. 1996), and western
blotting using antibodies to known phosphoserine and
phosphothreonine epitopes (Kobayashi et al. 2005; Wang
et al. 2006; Messer et al. 2007). These strategies can be quite
specific and relatively quantitative, but they seldom provide
a global (i.e. comprehensive) view of the chemical state of
these critical proteins. Developments in chromatography
and mass spectrometry (MS) have dramatically improved
the ability to identify peptides and localize protein modifi-
cations in a controlled proteolytic digest with sub-dalton
mass accuracy (i.e. the ‘bottom–up’ approach; Nesviszhsii
et al. 2007). Unfortunately, this strategy is also not com-
prehensive because some regions of the protein are not
represented in the peptide digest (sequence coverage is
incomplete) and quantification of peptides in a mixture
remains a significant challenge. Moreover, with digestion
the ‘connectivity’ between modified peptides from different
regions of the protein is lost, further precluding a compre-
hensive understanding of protein modifications, particularly
those that may be inter-dependent.
Mass analysis of intact proteins (i.e. the ‘top–down’
approach) offers the promise of a global assessment of post-
translational modifications and point mutations, including
the localization of protein modifications with nearly com-
plete sequence coverage (Ge et al. 2002; Han et al. 2006;
Kelleher et al. 1999; Siuti and Kelleher 2007; Zabrouskov
et al. 2008). The top–down strategy starts with highly
accurate molecular weight measurements of intact proteins
followed by fragmentation in the mass spectrometer of a
protein of interest by electron capture dissociation (ECD)
(McLafferty et al. 2001) or collisionally activated dissoci-
ation (CAD) (Senko et al. 1994), and accurate mass analysis
of the ensuing fragments to obtain primary sequence
information.
With the goal of obtaining a more complete view of the
chemical state of cTn subunits in native tissues, we report
here a strategy involving: (i) affinity purification of whole
troponin complexes (containing cTnI, cTnT and cTnC)
from a single rat heart (Messer et al. 2007) followed by (ii)
high resolution tandem mass spectrometry of the entire
complex without protease digestion (Zabrouskov et al.
2008). As expected, this strategy provides novel insights
into post-translational modification of cTnI and cTnT
including N-terminal processing, phosphorylation and
proteolysis. Unexpectedly, the technique also revealed
single amino acid sequence polymorphisms in both cTnI
and cTnT in normal healthy rat hearts. The polymorphisms
were shown to be an Ala to Ser substitution in residue 7 of
cTnI, and a likely alternative splice variant that affects a
putative hinge region of cTnT around residue 192. Some of
this data has been presented in preliminary form to the
American Biophysical Society (Sancho Solis et al. 2009).
Experimental procedures
Materials
All reagents were obtained from Sigma Chemical Co (St
Louis, MO, USA) unless noted otherwise. Complete prote-
ase inhibitor cocktail, trypsin (Sequencing grade, modified),
Lys-C (Endoproteinase Lys-C) or Glu-C (Endoproteinase
Glu-C) were from Roche (Mannheim, Germany).
Affinity purification of cTn
All procedures were approved by the University of Wisconsin
Animal Care and Use Committee. Whole cTn complexes
were affinity purified by the method of Messer et al. (2007)
with modifications. Briefly, hearts were surgically excised
from adult male Sprague–Dawley rats anesthetized with
isoflurane and rapidly washed with ice-cold Ringer’s
solution (125 mM NaCl, 5 mM KCl, 25 mM HEPES-
NaOH pH 7.4, 2 mM NaH2PO4, 1.2 mM MgSO4, 5 mM
Pyruvate and 11 mM D-glucose) to remove blood. Ven-
tricular tissue was homogenized for 4–6 s in relaxing
solution (100 mM KCl, 10 mM Imidazole, 6 mM MgCl2,
2 mM EGTA, 5 mM ATP, 1 mM PMSF, 1 mM DTT,
10 mM Benzamidine and 0.75 mg/ml protease inhibitor
cocktail) using a Polytron homogenizer. Cell fragments
were skinned (chemically permeabilized) in relaxing
solution containing 0.33% Triton-X-100 and 0.5 mg/ml
BSA for 4 min, washed twice then incubated in extraction
solution (0.7 M LiCl, 25 mM Tris pH 7.5, 5 mM EGTA,
0.1 mM CaCl2, 5 mM DTT, 1 mM PMSF and 0.75 mg/ml
protease inhibitor cocktail) for 1 h at 4C. Cell debris was
removed by centrifugation at 55,000 rpm for 45 min (80Ti
rotor, Beckman L-55 ultracentrifuge). The supernatant was
incubated with 0.3 ml of CNBr-activated Sepharose CL-4B
conjugated with a monoclonal cTnI antibody (anti-troponin
I monoclonal antibody MF4, Hytest, Finland) for 1 h at 4C
and then loaded into an empty disposable column. After
washing with 5 column volumes of extraction solution, the
column was eluted with 50 mM glycine pH 2 while 0.4 ml
fractions were collected and neutralized immediately by
80 ll of 1 M MOPS pH 9. Fractions were analyzed for
protein content by SDS-PAGE on 15% gels stained with
204 J Muscle Res Cell Motil (2008) 29:203–212
123
Coomassie Blue. Typically, four eluted fractions contained
cTn subunit bands at 17 kDa (cTnC), 27 kDa (cTnI) and
34 kDa (cTnT), with fraction 2 showing the darkest bands
and most consistent 1:1:1 stoichiometry (Fig. 1).
Top–down mass spectrometry
Immunoaffinity purified rat cTn complexes were desalted
using an offline reverse phase C18 protein microtrap
(Michrom Bioresources, Inc, CA), eluted first with 1%
acetic acid in 50:50 methanol:water and then 1% acetic
acid in 75:25 methanol:water. Samples were introduced to
the mass spectrometer using an automated chip-based
nanoESI source (Triversa NanoMate, Advion BioSciences,
Ithaca, NY) with a spray voltage of 1.4–1.6 kV versus the
inlet of the mass spectrometer, resulting in a flow of 50–
200 nl/min. Protein molecular ions were analyzed using a
linear trap/FTICR (LTQ FT Ultra) hybrid mass spectrom-
eter (Thermo Scientific Inc., Bremen, Germany). Ion
transmission into the linear trap (LT) and subsequently into
the FTICR cell was automatically optimized for maximum
ion signal. The number of accumulated ions for the full
scan LT, FTICR cell (FT), MSn FTICR cell and ECD were
3 9 104, 9 9 106, 8 9 106 and 5 9 106, respectively. The
resolving power of the FTICR mass analyzer was typically
set at 200,000 resulting in an acquisition rate of 1 scan/s.
Charge states of protein molecular ions were first isolated
and then dissociated by ECD using 2–3% ‘‘electron
energy’’ and a 45–150 ms duration with no delay. Isolated
charge states were also dissociated by CAD using collision
energies in the range of 10–22%. Typically, 500–3,000
transients were averaged to ensure high quality ECD or
CAD spectra. All FTICR spectra were processed with
Xtract Software (FT programs 2.0.1.0.6.1.4, Xcallibur
2.0.5, Thermo Scientific Inc., Bremen, Germany) using a
signal to noise threshold of 2 and fit factor of 40%, and
then validated manually. The resulting mass lists were
further assigned using in-house ‘‘Ion Assignment’’
software (Version 1.0) based on the protein sequence of rat
cTnI and cTnT obtained from Swiss-Prot protein knowl-
edgebase (primary accession numbers P23693 and P50753
isoform 2, respectively). Allowance was made for possible
post-translational modifications such as removal of initial
Met, acetylation of the N-terminus and variable phos-
phorylation sites, using a 0.1 Da tolerance for precursor
and fragment ions. All reported Mr values are most
abundant masses.
Bottom–up mass spectrometry
Immunoaffinity purified cTn complexes were reduced and
alkylated by incubation in 20 mM DTT for 10 min at 95C,
followed by incubation with 50 mM iodoacetic acid for
30 min at 37C. After pH was adjusted to 8.0 by addition of
50 mM bicarbonate, samples were incubated with trypsin,
Lys-C or Glu-C at a final ratio of 1:20 to 1:50 protease to
protein by weight and incubated overnight at 25C or 37C.
The reaction was terminated by addition of 4 ll of acetic
acid. The resulting peptide mixture was desalted using an
offline reverse phase C18 peptide microtrap (Michrom
Bioresources, Inc., CA) and analyzed using a linear trap/
FTICR (LTQ FT Ultra) hybrid mass spectrometer (Thermo
Scientific Inc., Bremen, Germany). Individual charge states
of candidate peptides were isolated and dissociated by ECD
(3–5% ‘‘electron energy’’ and 75–150 ms duration with no
delay) or CAD (12–25% collisional energies).
Results
Affinity purified cTn from adult rat heart showed three
major bands on Coomassie stained SDS-PAGE gels with
the expected molecular sizes of 17, 27 and 34 kDa (Fig. 1).
Mass spectrometry analysis of these purified protein
preparations consistently revealed complex charge state
envelopes and isotope patterns from which assignments
were made for full length cTnI (Fig. 2) and cTnT (Fig. 5).
Mass peaks for cTnC were seldom observed for reasons
that are not yet known. For cTnI, a strong signal was
observed for a species with most abundant mass of
24,069.72 Da which matched rat cTnI with the initial Met
removed and the new N-terminal Ala acetylated. Species
were also readily observed that matched this N-terminally
processed cTnI containing either one or two covalently
bound phosphoryl moieties (i.e. ?80 Da and ?160 Da).
Fig. 1 Affinity purification of cTn complexes from a single rat heart.
A representative 15% SDS-PAGE gel stained with Coomassie Blue.
Each lane represents different stages of the purification procedure: skn
skinned cardiac myofibrils; ext extracted cardiac contractile proteins;
FT column flow through; and E1–E4 fractions 1–4 collected during
low pH elution. Labels indicate apparent MW of markers (left) and
positions of cTnT, cTnI and cTnC (right). Weak Coomassie staining
of TnC has been documented by others (Yates and Greaser 1983)
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The intensity ratio for cTnI in its unphosphorylated (cTnI),
monophosphorylated (cTnI-P) and bisphosphorylated
(cTnI-PP) states averaged over spectra from 11 hearts was
41 ± 3%, 46 ± 1%, 13 ± 3%, respectively (Fig. 2).
The monophosphorylated species of cTnI (cTnI-P) was
isolated in the mass spectrometer and subjected to ECD
fragmentation to localize the phosphorylated residue(s).
Fragmentation patterns revealed that the vast majority of
phosphorylation in cTnI-P was at one of the two PKA
phosphorylation sites, Ser22 or Ser23 (Fig. 3). A definitive
localization to one of these sites was not possible because
the key fragmentation event between Ser22 and Ser23 was
not consistently observed. Further analysis of N-terminal
peptides generated by ‘in solution’ trypsin digestion of cTn
complexes did, however, place a phosphoryl moiety pre-
dominantly at Ser22 (data not shown), consistent with a
previous analysis of human cTnI (Zabrouskov et al. 2008).
In some preparations, a striking pattern of ‘parent’ and
‘shadow’ peaks of nearly identical intensity was observed
with masses equivalent to cTnI and cTnI?16 Da including
un-, mono- and bisphosphorylated forms of each (Fig. 2a).
In other preparations, only one set of these peaks was
observed: the ‘parent’ peaks at cTnI, cTnI-P and cTnI-PP,
or the corresponding ‘shadows’ peaks at cTnI?16, cTnI-
P?16 and cTnI-PP?16 Da (Fig. 2a). Out of 11 total hearts
analyzed, an equal mixture of ‘parent’ and ‘shadow’ peaks
occurred in seven hearts, parent peaks alone occurred in
one heart, and shadow peaks alone occurred in three hearts.
Isolation and fragmentation of the cTnI?16 Da peak
revealed a ?16 Da difference within the first 20 residues of
cTnI (Fig. 3). Further localization of this modification was
achieved by trypsin digestion to generate peptide fragments
that could be further sequenced by MS/MS (Fig. 4). This
analysis localized the 16 Da difference to residue 7 of
cTnI, placing an Ala or a Ser at this position. This sequence
polymorphism may have an impact on the extent of cTnI
phosphorylation as the Ser7 variant tended to display more
phosphorylation than the Ala7 variant (Fig. 2a), but
resolving this issue will require further investigation.
For cTnT, a strong signal was observed for a species
with mass of 34,442.44 Da which matched rat cTnT (adult
isoform 2) with the initial Met removed, the new N-ter-
minal Ser acetylated, and a single covalently bound
phosphoryl moiety (?80 Da) (Fig. 5). Unphosphorylated
cTnT represented 10% of the total intensity of intact cTnT
indicating that the majority of cTnT was constitutively
monophosphorylated (cTnT-P), possibly on a single site as
bisphosphorylated cTnT was not detected. A major protein
ion was also detected with mass of 30,950.17 Da (Fig. 5)
and subsequently shown by ECD to be a cTnT fragment
consisting of residues Pro30 to Lys288. Specifically, isola-
tion and ECD fragmentation of the M38? peak at
30,950.17 Da produced 7 c-ions that matched the N-ter-








and 40 z-ions that matched its C-terminus (data not shown).
Importantly, this cTnT30-288 fragment was not N-termi-
nally acetylated (nor were any of its ECD generated c-ions)
suggesting that it arose through proteolysis rather than
via a secondary transcription/translation start site or via
alternative mRNA splicing (see section ‘‘Discussion’’).
cTnT30-288 was also not phosphorylated suggesting that
full length cTnT-P was phosphorylated within the first 29
residues of its N-terminus. ECD fragmentation of intact
cTnT-P further indicated that there was no detectable
phosphorylation between Ser198 and the C-terminus,
thereby ruling out significant basal phosphorylation of PKC
Fig. 2 cTnI isoforms in rat heart. a ESI/FTMS spectrum of cTnI
protein ions from a rat expressing both cTnI and a cTnI?16 Da
variant in unphosphorylated, monophosphorylated (?1P) and bi-
phosphorylated (?2P) states (top panel). ESI/FTMS spectra of cTnI
proteins ions expressing only one of the cTnI variants in its
phosphorylated states (middle and bottom panels). b Isotopically
resolved cTnI molecular ion in the ?31 charge state (M31?). Circles
represent the theoretical abundance isotopic distribution for cTnI
(Swiss-Prot TNNI3_RAT, primary accession number P23693) with
calculated most abundant mass for cTnI-Met?acetyl of 24069.73 Da
corresponding to the experimental most abundant mass of
24069.72 Da. Na? indicates sodium ion adducts of primary peaks
at ?22 Da
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sites Ser198 and Thr203 (data not shown). However, top–
down ECD and protease digestion of cTnT-P both failed to
narrow down phosphorylation site(s) further, possibly due
to the highly acidic nature of the N-terminus of cTnT.
Another major peak was observed with extensive
sequence similarity to cTnT-P, but differed in its overall
mass by 128 Da (Fig. 5a). Addition or subtraction of
C-terminal Lys (equivalent to 128 Da) was ruled out by
numerous ECD generated z-ions that revealed retention of a
single C-terminal Lys. Moreover, the ECD data clearly
showed that the 128 Da addition was not contained between
Ser198 and the C-terminus of cTnT. Glu-C digestion was
then employed to generate candidate peptides that contained
the ?128 Da mass difference. Two peptides were observed
that matched the mass of an internal cTnT peptide at Ala173
to Glu195 and Ala173 to Glu195?128 Da (Fig. 6). The two
peptides were isolated and subjected to MS/MS by CAD.
Indeed, one peptide matched the sequence of a 23 amino
acid peptide from residues 173 to 195 of cTnT (Fig. 6a). The
other peptide matched the sequence of a 24 amino acid
peptide with an extra 128 Da at residue 20 (Fig. 6b).
Therefore, the tandem MS/MS data of these peptides placed
an extra Lys or Gln at residue 20 of this peptide, equivalent
to residue 192 of full length rat cTnT (Fig. 6). As described
in the section ‘‘Discussion,’’ these observations can be
accounted for by the presence of two alternatively spliced
variants of cTnT that include or delete a Gln at position 192
of the protein sequence.
Discussion
In this study we describe a high resolution top–down mass
spectrometry strategy to examine the biochemical state of
cardiac troponin (cTn) subunits isolated from rat heart.
Affinity chromatography with a well-characterized mono-
clonal antibody resin was employed to rapidly purify cTn
complexes from rat heart homogenates. The entire
Fig. 3 Top–down MS/MS
analysis of monophosphorylated
cTnI?16 Da variant. a ECD
spectrum of molecular ion at m/
z 834.3. b Cleavage
assignments of the ECD
spectrum as in A mapped onto
the cTnI sequence (Swiss-Prot
primary accession number
P23693). Phosphorylated ions
labeled ‘‘p’’ in the ECD
spectrum.
Monophosphorylation localized
to the Ser22/23 cluster indicated
by a ‘‘p’’ in the protein
sequence. * indicates ions
detected with ?16 Da
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complex, after desalting, was then subjected to mass
spectrometry to reveal masses of intact cTnI and cTnT, as
well as prominent post-translationally modified forms. The
use of high resolution top–down mass spectrometry offered
significant advantages for the identification and quantifi-
cation of single amino acid sequence variants of the cTn
subunits. Also key to the analysis was peptide backbone
fragmentation in the gas phase by ECD and CAD, in
combination with ‘in solution’ proteolytic digestion that
allowed for extensive peptide/protein sequencing, and thus
for precise localization of observed sequence heterogene-
ities and other modifications.
An apparent genetic polymorphism was observed here at
the protein level for cTnI expressed in Sprague–Dawley rat
hearts. This polymorphism has been detected previously at
the mRNA level by sequence analysis of rat heart cDNA
clones (Martin and Orlowski 1991). We confirm here that
the polymorphism at position 7 of rat cTnI occurs at the
protein level and within a single heart. The functional
significance of this apparent ‘allelic’ polymorphism remains
an open question.
Monophosphorylated cTnI was predominantly phos-
phorylated on Ser22, the N-terminal side of the vicinal
Ser22/23 pair targeted by protein kinase A. This result is
similar to what was observed in a top–down mass spec-
trometry analysis of human cTnI (Zabrouskov et al. 2008).
In that study, preferential phosphorylation of Ser22 was
interpreted to indicate that phosphor-Ser22 is the thermo-
dynamically favored site in vivo, despite the fact that the
Ser23 site (the C-terminal side of the pair) appears to be
kinetically favored by protein kinase A in vitro (Jaquet
et al. 1995; Zhang et al. 1995; Keane et al. 1997; Sancho
Solis and Walker unpublished). This apparent paradox can
be accounted for by assuming that in vivo a phosphatase
complementary to the kinase dephosphorylates Ser23 more
quickly than Ser22. In such a system, Ser22 would behave as
the more stable (but still slowly turning over) site of
modification, while Ser23 would turn over much more
Fig. 4 Identification of Ala or
Ser at position 7 in cTnI by
bottom–up mass spectrometry.
Precursor ions (insets) and their
CAD spectra are illustrated for
N-terminal tryptic peptides (A1-
R19, sequences shown) obtained
by digestion of purified cTn
complexes. a cTnI Ala1-Arg19
with Ala7. b cTnI Ala1-Arg19
with S7. Similar results were
obtained with N-terminal tryptic
peptides Ala1-Arg20 (not
shown)
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rapidly. Intriguingly, in such an arrangement, phospho-
Ser22 may serve as a steady state indicator of the recent
history of activation by b-stimulation and protein kinase A,
and would effectively serve to prime the system for more
rapid onset of biological effects. One important difference
between the rat cTnI results described here and the earlier
results with human cTnI is that the human samples dis-
played a second prominent monophosphorylation site at
Ser76 or Thr77 (Zabrouskov et al. 2008). This may reflect a
limitation of the earlier study in which human cTnI,
obtained commercially from Sigma-Aldrich or Calbio-
chem, was purified from mixtures of tissue obtained from
multiple hearts. In contrast, the rat data described here were
from single healthy rat hearts. The source of the human
tissue is less well defined although company technical
support believes it to be from ‘healthy’ human heart tissue.
Analysis of rat cTnT in the present study revealed its own
unique forms of molecular heterogeneity. cTnT was
observed to be predominantly monophosphorylated
accounting for 90% of the intensity of full length cTnT in the
mass spectra. We were unable to localize the monophosph-
orylation site(s) in rat cTnT with any precision, although
ECD of cTnT-P did argue strongly against basal
phosphorylation in the C-terminus downstream of residue
197 including Ser198 and Thr203 which are putative PKC
phosphorylation sites (Sumandea et al. 2003). Studies in a
variety of animal species have established Ser1 of cTnT as a
common phosphorylation site targeted by casein kinase 2 and
often basally phosphorylated to near stoichiometric levels
(Gusev et al. 1983; Risnik et al. 1985; Leszyk et al. 1987;
Swiderek et al. 1990). Interestingly, the present data provided
virtually no sequence information in the N-terminal region of
cTnT using either top–down analysis (i.e. no c-ions were
observed) or bottom–up analysis (i.e. no N-terminal proteo-
lytic peptides were detected). This may be a reflection of the
unique composition of the N-terminus of cTnT which con-
tains among its first 41 residues 25 acidic amino acids (Glu or
Asp), no basic residues (Arg or Lys), and exhibits a strongly
acidic pI (isoelectric point) of less than 3. Thus, while the
conditions employed in this study were not optimized for
mass analysis of highly acidic peptides, and may have
precluded the precise localization of the phosphoryl moiety
in monophosphorylated cTnT, our data are consistent with
constitutive phosphorylation of Ser1 in this species.
Considerable insight on this and other issues was
provided by a detailed mass analysis of a prominent cTnT-
Fig. 5 cTnT isoforms in rat
heart. a ESI/FTMS spectrum of
cTnT protein ions displaying
cTnT and a cTnT?128 Da
variant in unphosphorylated and
monophosphorylated (?1P)




molecular ions of M42?
monophosphorylated cTnT
(left) and M38? cTnT30-288
(right). Circles represent the
theoretical abundance of the
isotopic distribution for cTnT
(Swiss-Prot TNNT2_RAT,
primary accession number
P50753-2) with calculated most
abundant mass for cTnT-
Met?acetyl?P of
34442.41 Da corresponding to
the experimental most abundant
mass of 34442.44 Da (left). The
same TNNT2_RAT protein
sequence was used to calculate
most abundant mass for
cTnT30-288 without
modifications (no acetyl, no P)
of 30950.14 Da corresponding
to the experimental most
abundant mass of 30950.17 Da
(right). Na? indicates sodium
adducts of primary peaks at
?22 Da
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related species at 30,950.17 Da. Its mass matched with
\5 ppm mass accuracy the predicted mass of a cTnT
fragment containing residues 30–288; moreover, ECD
generated a multitude of matching fragment ions covering
both the N- and C-termini of this cTnT30-288 species.
Importantly, the N-terminus of this version of cTnT was
not acetylated suggesting that it arose from proteolysis of
full length cTnT rather than via other transcriptional or
translational mechanisms capable of generating protein
diversity. Mass data of this quality and precision also vir-
tually completely rules out the possibility that this cTnT
species arose from an unusual or unknown mRNA splicing
event, an important consideration for cTnT which can be
extensively spliced (Biesiakecki et al. 2002). With regard
to localization of phosphoryl moieties in cTnT-P, identifi-
cation of cTnT30-288 also provided evidence for cTnT-P
phosphorylation in the first 29 residues, as cTnT30-288
was consistently not phosphorylated.
In retrospect, proteolytic processing of cTnT as evi-
denced by the presence of cTnT30-288 is not surprising, as
the highly acidic N-terminal domain is predicted to be
disordered and unstable. cTnT has been shown to be pro-
teolytically processed at its N-terminus with pronounced
effects on in vivo rat heart function (Feng et al. 2008). In
that case, the predominant proteolytic event removed 71
residues from the N-terminus of cTnT compared to 29
residues observed here. A 26,400 Da fragment that could
have arisen from removal of a 71 residue N-terminal
domain was occasionally observed in our mass spectra, but
only at very low levels that precluded further analysis by
MS/MS fragmentation. A better understanding of mecha-
nisms and consequences associated with proteolytic
processing of the highly acidic N-terminal domain of cTnT
will require further investigation.
A single amino acid variant at ?128 Da was also
detected for rat heart cTnT, with peak intensity represent-
ing approximately 40% of the total cTnT peak intensity in
the spectra. A ?128 Da variant was also associated with
the cTnT30-288 proteolytic fragment of cTnT. Top–down
and bottom–up analysis of cTn unequivocally localized this
Fig. 6 Localization of
sequence heterogeneity in an
endoprotease Glu-C peptide of
cTnT. Peptides with masses that
matched. a cTnT Ala173-Glu195
and b cTnT Ala173-
Glu195?128 Da were isolated
(insets), and subjected to
sequence analysis by CAD
fragmentation (upper and
bottom panels). Peptide
sequences are labeled with
bonds cleaved and fragment
ions detected
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?128 Da difference to residue 192 of cTnT, a mass dif-
ference that could be due to the presence of an additional
Gln or Lys at this location. Sequencing of genomic DNA
clones of rat cTnT has revealed the presence of a 9 bp exon
(exon 12) that encodes a tripeptide Gln-Ala-Gln (Jin et al.
1992). Sequence analysis of cDNA clones further revealed
that exon 12 is alternatively spliced in three ways: class I
splicing retains the entire tripeptide in the sequence; class
II splicing retains only Ala-Gln; and class III isoforms have
the entire tripeptide spliced out. In that study, class II
splicing was estimated to account for *80% of the cTnT
protein expressed in rat heart (Jin et al. 1992). The most
straight forward interpretation of the mass spectral data
presented here is that the presence of ?128 Da at residue
192 is due to class I splicing (inclusion of the entire tri-
peptide), whereas class II splicing would account for the
peak lacking one Gln (-128 Da). According to this inter-
pretation, class I splicing accounted for *40% of cTnT
expressed in these Sprague–Dawley rat hearts, class II
splicing (lacking Gln) accounted for *60% of cTnT
expressed, and class III splicing with the entire tripeptide
removed was undetected and thus not expressed at signif-
icant levels.
The functional significance of this splice heterogeneity
remains to be determined, although it has been proposed
that this region functions as a linker between distinct cTnT
domains, namely the intrinsically disordered N-terminal
Tm binding domain and the cTnI binding cTnT1 domain
(Harada and Morimoto 2004). Importantly, the present data
clearly shows that heterogeneity in the length (and/or
composition) of this putative linker occurs within a single
rat heart. The present data were collected on combined
right and left ventricular tissue of individual hearts, so
whether or not this cTnT splice heterogeneity is distributed
evenly throughout the heart remains to be explored.
Analysis of molecular forms of cTnT within atrial versus
ventricular tissues, from the right versus left heart cham-
bers, or even transmurally across the ventricular walls may
require improvements in methodology including enhanced
mass spectrometer sensitivity and better protein recovery
during purification and desalting.
Finally, it is of interest to determine how these single
amino acid polymorphisms in cTn subunits alone or in
combination might impact rat heart function. Understand-
ing the Ala7/Ser7 polymorphism in cTnI may be more
tractable as our methodology can be used to establish the
‘genotype’ of these rats at this locus. A systematic analysis
of cardiac function prior to genotyping by isolation and
mass spectrometry of cTn could be used to reveal func-
tional differences between Ala7 and Ser7 variants, as well
as to establish the properties of ‘heterozygotes’. To eval-
uate the functional implications of the cTnT sequence
variants, whose ratio does not appear to vary from animal
to animal, may require in vitro functional assays in skinned
muscles wherein the composition of cTn can be controlled
by reconstitution or subunit exchange (Solaro 2008).
Acknowledgements The authors thank Dr. Andrew Messer and
Professor Steven Marston for invaluable assistance with methods for
affinity purification of troponin and for many helpful discussions. The
authors also thank Christopher Doede, Jennifer Wachholz and Lisa
Xu for expert technical assistance during early stages of the project.
This work was supported by an American Heart Association Scientist
Development Grant (YG), the Wisconsin Partnership for a Healthy
Future, and NIH grant RO1 HL081386 (JWW).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Biesiakecki BJ, Elder BD, Zhi-Bin Y, Jin JP (2002) Cardiac troponin
T variants produced by aberrant splicing of multiple exons in
animals with high instances of dilated cardiomyopathy. J Biol
Chem 277:50275–50285. doi:10.1074/jbc.M206369200
Feng HZ, Biesdiadecki BJ, Yu ZB, Hossain MM, Jin JP (2008)
Restricted N-terminal truncation of cardiac troponin T: a novel
mechanism for functional adaptation to energetic crisis. J Physiol
586:3537. doi:10.1113/jphysiol.2008.153577
Ge Y, Lawhorn BG, ElNaggar M, Strauss E, Park JH, Begley TP,
McLafferty FW (2002) Top down characterization of larger
proteins (45 kDa) by electron capture dissociation mass spec-
trometry. J Am Chem Soc 124:672–678. doi:10.1021/ja011335z
Gusev NB, Barskaya NV, Verin AD, Duzhenkova IV, Khuchua ZA,
Zheltova AO (1983) Some properties of cardiac troponin T
structure. Biochem J 213:123–129
Han XM, Jin M, Breuker K, McLafferty FW (2006) Extending top-
down mass spectrometry to proteins with masses greater than
200 kilodaltons. Science 314:109–112. doi:10.1126/science.11
28868
Harada K, Morimoto S (2004) Inherited cardiomyopathies as a
troponin disease. Jpn J Physiol 54:307–318. doi:10.2170/
jjphysiol.54.307
Jaffe AS, Babuin L, Apple FS (2006) Biomarkers in acute cardiac
disease: the present and the future. J Am Coll Cardiol 48:1–11.
doi:10.1016/j.jacc.2006.02.056
Jaquet K, Thieleczek R, Heilmeyer LM (1995) Pattern formation on
cardiac troponin I by consecutive phosphorylation and dephos-
phorylation. Eur J Biochem 231:329–337. doi:10.1111/j.1432-
1033.1995.tb20722.x
Jideama NM, Noland TA Jr, Raynor RL, Blobe GC, Fabbro D,
Kazanietz MG, Blumberg PM, Hannun YA, Kuo JF (1996)
Phosphorylation specificities of protein kinase C isozymes for
bovine cardiac troponin I and troponin T and sites within these
proteins and regulation of myofilament properties. J Biol Med
271:23277–23283
Jin JP, Huang QQ, Yeh HI, Ling JJC (1992) Complete nucleotide
sequence and structural organization of the rat cardiac troponin T
gene. J Mol Biol 227:1269–1276. doi:10.1016/0022-2836(92)
90540-Z
Keane NE, Quirk PG, Gao Y, Patchell VB, Perry SV, Levine BA
(1997) The ordered phosphorylation of cardiac troponin I by the
cAMP-dependent protein kinase: structural consequences and
J Muscle Res Cell Motil (2008) 29:203–212 211
123
functional implications. Eur J Biochem 248:329–337. doi:
10.1111/j.1432-1033.1997.00329.x
Kelleher NL, Lin HY, Valaskovic GA, Aaserud DJ, Fridriksson EK,
McLafferty FW (1999) Top down versus bottom up protein
characterization by tandem high-resolution mass spectrometry. J
Am Chem Soc 121:806–812. doi:10.1021/ja973655h
Kobayashi T, Yang X, Walker LA, Van Breemen RB, Solaro RJ
(2005) A non-equilibrium isoelectric focusing method to deter-
mine states fo phosphorylation of cardiac troponin I:
identification of Ser-23 and Ser-24 as significant sites of
phosphorylation by protein kinase C. J Mol Cell Cardiol
38:213–238. doi:10.1016/j.yjmcc.2004.10.014
Leszyk J, Dumaswala R, Potter JD, Gusev NB, Verin AD, Tobacman
LS, Collins JH (1987) Bovine cardiac troponin T: amino acid
sequence of the two isoforms. Biochemistry 26:7035–7042. doi:
10.1021/bi00396a027
Martin AF, Orlowski J (1991) Molecular cloning and developmental
expression of the rat cardiac-specific isoform of troponin I. J Mol
Cell Cardiol 23:583–588. doi:10.1016/0022-2828(91)90050-V
McLafferty FW, Horn DM, Breuker K, Ge Y, Lewis MA, Cerda B,
Zubarev RA, Carpenter BK (2001) Electron capture dissociation
of gaseous multiply charged ions by Fourier-transform ion
cyclotron resonance. J Am Soc Mass Spectrom 3:245–249
Messer AE, Jacques AM, Marston SB (2007) Troponin phosphory-
lation and regulatory function in human heart muscle:
dephosphorylation of Ser23/24 on troponin I could account for
the contractile defect in end-stage heart failure. J Mol Cell
Cardiol 42:247–259. doi:10.1016/j.yjmcc.2006.08.017
Murphy AM (2006) Heart failure, myocardial stunning and troponin:
a key regulator of the cardiac myofilament. Congest Heart Fail
12:32–38. doi:10.1111/j.1527-5299.2006.04320.x
Nesviszhsii AI, Vitek O, Aebersold R (2007) Analysis and validation
of proteomic data generated by tandem mass spectrometry. Nat
Methods 4:787–797. doi:10.1038/nmeth1088
Pi YQ, Kemnitz KR, Zhang D, Kranias E, Walker JW (2002)
Phosphorylation of troponin I controls cardiac twitch dynamics.
Evidence from phosphorylation site mutations expressed on a
troponin I null background in mice. Circ Res 90:649–656. doi:
10.1161/01.RES.0000014080.82861.5F
Pi YQ, Zhang D, Kemnitz KR, Wang H, Walker JW (2003) Protein
kinase C and A sites on troponin I regulate myofilament Ca2?
sensitivity and ATPase rate in mouse myocardium. J Physiol
552:845–857. doi:10.1113/jphysiol.2003.045260
Risnik VV, Verin AD, Gusev NB (1985) Comparison of the structure
of two cardiac troponin T isoforms. Biochem J 225:549–552
Sancho Solis R, Ge Y, Walker JW (2009) High resolution top-down
MS/MS reveals single amino acid sequence polymorphisms in
rat cardiac troponin. 2009 Biophysical Society Meeting Abstract,
Biophys J, Supplement, Abstract
Senko MW, Speir JP, McLafferty FW (1994) Collisional activation of
large multiply-charged ions using Fourier-transform mass-spec-
trometry. Anal Chem 66:2801–2808. doi:10.1021/ac00090a003
Siuti N, Kelleher NL (2007) Decoding protein modifications using
top-down mass spectrometry. Nat Methods 4:817–821. doi:
10.1038/nmeth1097
Solaro RJ (2008) Multiplex kinase signaling modifies cardiac function
at the level of sarcomeric proteins. J Biol Chem 283:26829–
26833. doi:10.1074/jbc.R800037200
Sumandea MP, Pyle WG, Kobayashi T, de Tombe PP, Solaro RJ
(2003) Identification of a functionally critical protein kinase C
phosphorylation residue of cardiac troponin T. J Biol Chem
278:35135–35144. doi:10.1074/jbc.M306325200
Swiderek K, Jaquet K, Meyer HE, Schachtele C, Hofmann F,
Heilmeyer LM (1990) Sites phosphorylated in bovine cardiac
troponin T and I. Characterization by 31P-NMR spectroscopy
and phosphorylation by protein kinases. Eur J Biochem
190:575–582. doi:10.1111/j.1432-1033.1990.tb15612.x
Vahebi S, Kobayashi T, Warren CM, de Tombe PP, Solaro RJ (2005)
Functional effects of rho-kinase-dependent phosphorylation of
specific sites on cardiac troponin. Circ Res 96:740–747. doi:
10.1161/01.RES.0000162457.56568.7d
Wang H, Grant JE, Doede CM, Sakthivel S, Robins J, Walker JW
(2006) PKC-betaII sensitizes cardiac myofilaments to Ca2? by
phosphorylating troponin I on threonine-144. J Mol Cell Cardiol
41:823–833. doi:10.1016/j.yjmcc.2006.08.016
Yates LD, Greaser ML (1983) Troponin subunit stoichiometry and
content in rabbit skeletal muscle and myofibrils. J Biol Chem
258:5770–5774
Zabrouskov V, Ge Y, Schwartz J, Walker JW (2008) Unraveling
molecular complexity of phosphorylated human cardiac troponin
I by top down electron capture dissociation/electron transfer
dissociation mass spectrometry. Mol Cell Proteomics 7:1838–
1849. doi:10.1074/mcp.M700524-MCP200
Zhang R, Zhao J, Potter JD (1995) Phosphorylation of both serine
residues in cardiac troponin I is required to decrease the Ca2?
affinity of cardiac troponin C. J Biol Chem 270:30773–30780.
doi:10.1074/jbc.270.51.30773
212 J Muscle Res Cell Motil (2008) 29:203–212
123
